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Outputs
• Antibody repertoires of > 30 cows sequenced, 
including several from indigenous African 
breeds such as Ankole, Ndama and Boran.
• Antibody repertoire characteristics of African 
breeds differ from those of exotic breeds.
• Putative antigen-specific antibodies identified 
against an ECF vaccine candidate.
• Novel alleles for immunoglobulin genes 
identified in African bovine breeds.
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High throughput immune repertoire analysis by next-generation sequencing and 
bioinformatics provides qualitative and quantitative molecular information on 
antigen-specific responses.
Context
• To understand antibody responses to infection 
and vaccination so as to help design better 
vaccines.
• Use antigen-specific antibodies to home in on 
critical components of antigens for use in 
vaccine development.
• Add to the immunogenetic knowledge on 
African bovine breeds.
• Developed the technology on East Coast Fever 
(ECF) experimental vaccine studies.
Our innovative approach
• To apply high throughput sequencing 
technology to characterize the quality of 
antibody response to immunization.
• Developed a novel strategy to capture the 
unusually long antibodies found only in bovines 
that could have broadly neutralizing capacity.
• Established pipeline for bioinformatics analysis 
on ILRI’s high performance computer.
Future steps 
• Recombinant antigen-specific antibodies will be 
synthesized and tested for neutralizing activity.
• This technology can be applied to study immune 
responses to other diseases of cattle, other 
ruminants as well as humans.
• Antibody-based therapeutics can be developed 
from the sequence of protective antibodies.
• Scaling is possible through automation of the 
analysis pipeline.
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